AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

The motivation behind seeking an answer to the question “Is RNAi of target X likely to induce the same phenotype as a small-molecule inhibitor of target X?” is two-fold. First, in a target ...

a novel therapeutic agent targeting human epidermal growth factor receptor 2 (HER2)-driven cancers. A selective and brain-penetrant small molecule inhibitor, IAM1363, has been designed to expand ...

The US company also sells a small-molecule HER2 inhibitor – Tukysa (tucatinib) – which is now partnered with Merck & Co outside the US, Canada and Europe as part of a $4.2 billion alliance ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

17, 2025 (GLOBE NEWSWIRE) -- HER2+ Non-Small Cell Lung Cancer Market is Predicted ... the highest revenue was generated by Checkpoint inhibitors ± Chemotherapy, i.e., USD ~480 million in the ...

BAY 2927088 is an oral small-molecule tyrosine kinase inhibitor designed to selectively target mutant HER2, including HER2 exon 20 insertions and point mutations, as well as EGFR while maintaining ...

As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...